These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 35053476)
41. Anticancer effects of combinational treatment with BRAF He H; Nan X; Liu S; Zhang L; Yang Z; Wu Y; Zhang L Oncol Lett; 2018 Jul; 16(1):632-642. PubMed ID: 29928450 [TBL] [Abstract][Full Text] [Related]
42. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications. Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796 [TBL] [Abstract][Full Text] [Related]
43. RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells. Zhao K; Lu Y; Chen Y; Cheng J; Zhang W Data Brief; 2020 Jun; 30():105610. PubMed ID: 32382617 [TBL] [Abstract][Full Text] [Related]
44. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329 [TBL] [Abstract][Full Text] [Related]
45. Vemurafenib enhances MHC induction in BRAF Sapkota B; Hill CE; Pollack BP Oncoimmunology; 2013 Jan; 2(1):e22890. PubMed ID: 23483066 [TBL] [Abstract][Full Text] [Related]
46. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239 [TBL] [Abstract][Full Text] [Related]
47. RSK2 promotes melanoma cell proliferation and vemurafenib resistance Wu HZ; Li LY; Jiang SL; Li YZ; Shi XM; Sun XY; Li Z; Cheng Y Front Pharmacol; 2022; 13():950571. PubMed ID: 36210843 [TBL] [Abstract][Full Text] [Related]
48. The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells. Yu L; Favoino E; Wang Y; Ma Y; Deng X; Wang X Immunol Res; 2011 Aug; 50(2-3):294-302. PubMed ID: 21717063 [TBL] [Abstract][Full Text] [Related]
49. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases. Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704 [TBL] [Abstract][Full Text] [Related]
50. ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs). Prasetyanti PR; Capone E; Barcaroli D; D'Agostino D; Volpe S; Benfante A; van Hooff S; Iacobelli V; Rossi C; Iacobelli S; Medema JP; De Laurenzi V; Sala G Oncotarget; 2015 Jul; 6(19):16902-11. PubMed ID: 26160848 [TBL] [Abstract][Full Text] [Related]
51. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656 [TBL] [Abstract][Full Text] [Related]
52. LKB1 loss cooperating with BRAF V600E promotes melanoma cell invasion and migration by up-regulation MMP-2 via PI3K/Akt/mTOR pathway. Zhang W; Yin L; Song G; Han X; Yin Z; Luo D Oncotarget; 2017 Dec; 8(69):113847-113857. PubMed ID: 29371951 [TBL] [Abstract][Full Text] [Related]
53. Glucocorticoid receptor antagonism overcomes resistance to BRAF inhibition in BRAF Estrela JM; Salvador R; Marchio P; Valles SL; López-Blanch R; Rivera P; Benlloch M; Alcácer J; Pérez CL; Pellicer JA; Obrador E Am J Cancer Res; 2019; 9(12):2580-2598. PubMed ID: 31911848 [TBL] [Abstract][Full Text] [Related]
54. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma. Jain A; Tripathi R; Turpin CP; Wang C; Plattner R Oncogene; 2017 Aug; 36(32):4585-4596. PubMed ID: 28368422 [TBL] [Abstract][Full Text] [Related]
55. HMG-CoA synthase 1 is a synthetic lethal partner of BRAF Zhao L; Fan J; Xia S; Pan Y; Liu S; Qian G; Qian Z; Kang HB; Arbiser JL; Pollack BP; Kudchadkar RR; Lawson DH; Rossi M; Abdel-Wahab O; Merghoub T; Khoury HJ; Khuri FR; Boise LH; Lonial S; Chen F; Chen J; Lin R J Biol Chem; 2017 Jun; 292(24):10142-10152. PubMed ID: 28468827 [TBL] [Abstract][Full Text] [Related]
56. Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis Wang L; Otkur W; Wang A; Wang W; Lyu Y; Fang L; Shan X; Song M; Feng Y; Zhao Y; Piao HL; Qi H; Liu JW Front Pharmacol; 2022; 13():906043. PubMed ID: 36034784 [TBL] [Abstract][Full Text] [Related]
57. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Das Thakur M; Salangsang F; Landman AS; Sellers WR; Pryer NK; Levesque MP; Dummer R; McMahon M; Stuart DD Nature; 2013 Feb; 494(7436):251-5. PubMed ID: 23302800 [TBL] [Abstract][Full Text] [Related]